PharmacyCodes



Nadolol en es it fr

Nadolol Brand names, Nadolol Analogs

Nadolol Brand Names Mixture

  • Corzide Tab W Nadolol 40mg (Bendroflumethiazide + Nadolol)
  • Corzide Tab W Nadolol 80mg (Bendroflumethiazide + Nadolol)

Nadolol Chemical_Formula

C17H27NO4

Nadolol RX_link

http://www.rxlist.com/cgi/generic3/nadolol.htm

Nadolol fda sheet

Nadolol msds (material safety sheet)

Nadolol Synthesis Reference

F. P. Hauck et al., U.S. Pat. 3,935,267 (1976)

Nadolol Molecular Weight

309.401 g/mol

Nadolol Melting Point

124-136 oC

Nadolol H2O Solubility

8330 mg/L

Nadolol State

Solid

Nadolol LogP

1.398

Nadolol Dosage Forms

Tablets (20 mg, 40 mg, 80 mg, 120 mg, and 160 mg)

Nadolol Indication

Used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension.

Nadolol Pharmacology

Nadolol is a nonselective beta-adrenergic receptor antagonist with a long half-life, and is structurally similar to propranolol. Clinical pharmacology studies have demonstrated beta-blocking activity by showing (1) reduction in heart rate and cardiac output at rest and on exercise, (2) reduction of systolic and diastolic blood pressure at rest and on exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia. Nadolol has no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, nadolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action.

Nadolol Absorption

Absorption of nadolol after oral dosing is variable, averaging about 30 percent.

Nadolol side effects and Toxicity

Oral, mouse: LD50 = 4500mg/kg. Symptoms of overdose include abdominal irritation, central nervous system depression, coma, extremely slow heartbeat, heart failure, lethargy, low blood pressure, and wheezing.

Nadolol Patient Information

Patients, especially those with evidence of coronary artery insufficiency, should be warned against interruption or discontinuation of nadolol therapy without the physician's advice. Although cardiac failure rarely occurs in properly selected patients, patients being treated with beta-adrenergic blocking agents should be advised to consult the physician at the first sign or symptom of impending failure. The patient should also be advised of a proper course in the event of an inadvertently missed dose.

Nadolol Organisms Affected

Humans and other mammals